{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:20:12Z","timestamp":1783070412342,"version":"3.54.6"},"reference-count":63,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is widely used in multiple myeloma and AL amyloidosis. Despite its clinical success, many patients fail to achieve durable responses or relapse, underscoring the importance of understanding resistance mechanisms. Drawing on experience from other better-studied monoclonal antibodies, resistance to daratumumab can be categorized into four main mechanisms: (1) reduced CD38 expression on plasma cells; (2) increased expression of complement inhibitory proteins (CD55\/CD59), impairing complement-mediated cytotoxicity; (3) reduced drug bioavailability due to urinary loss in non-selective nephrotic syndrome; and (4) the development of neutralizing anti-daratumumab antibodies. Anti-drug antibodies (ADAs) may represent a potential mechanism of treatment failure through effects on pharmacokinetics, efficacy, and safety, even in patients on daratumumab therapy. Seven different trials have tested anti-daratumumab antibodies. Among them, anti-daratumumab antibodies were identified in only 0\u20132.4% of patients, and only in a small portion of these has it been proven to be neutralizing. Overall, ADAs appear rare, but these findings are likely underestimated due to short follow-up and suboptimal timing of assessment. In conclusion, standardized ADA monitoring, particularly months after treatment interruption or in cases of inadequate response or infusion-related reactions, may improve patient management and therapeutic outcomes.<\/jats:p>","DOI":"10.3390\/antib15040057","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:59:47Z","timestamp":1783065587000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Mechanisms of Partial\/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3543","authenticated-orcid":false,"given":"Marco","family":"Allinovi","sequence":"first","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, 50134 Florence, Italy"},{"name":"Tuscan Regional Amyloidosis Centre, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8534-9441","authenticated-orcid":false,"given":"Luca","family":"Malatesta","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-0980","authenticated-orcid":false,"given":"Tiziana","family":"Biagioli","sequence":"additional","affiliation":[{"name":"General Laboratory, Department of Diagnostics, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[{"name":"Haematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0276-8331","authenticated-orcid":false,"given":"Federico","family":"Perfetto","sequence":"additional","affiliation":[{"name":"Tuscan Regional Amyloidosis Centre, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"ref_1","first-page":"132","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","volume":"7","author":"Strohl","year":"2024","journal-title":"Antib. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107357","DOI":"10.1016\/j.ejps.2025.107357","article-title":"Evaluation of anti-drug antibodies against therapeutic monoclonal antibodies and related product in Japanese patients with rheumatoid arthritis and their clinical impact","volume":"216","author":"Shibata","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Moots, R.J., Xavier, R.M., Mok, C.C., Rahman, M.U., Tsai, W.C., Al-Maini, M.H., Pavelka, K., Mahgoub, E., Kotak, S., and Korth-Bradley, J. (2017). The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE, 12, Erratum in PLoS ONE\u00a02017, 12, e0179308. https:\/\/doi.org\/10.1371\/journal.pone.0179308.","DOI":"10.1371\/journal.pone.0179308"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ekir.2025.04.059","article-title":"Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy","volume":"10","author":"Allinovi","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Saraga, A., Deyhim, T., Gade, A., Geeganage, G., Soliman, M., Rothschild, N.D.V., Zullow, S., Rabinowitz, L.G., Grossberg, L.B., and Cheifetz, A.S. (2026). Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel Disease. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020547"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","article-title":"Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins","volume":"35","author":"Jarvi","year":"2021","journal-title":"BioDrugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12248-024-00930-w","article-title":"Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route","volume":"26","author":"Felderman","year":"2024","journal-title":"AAPS J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jmb.2009.12.046","article-title":"Engineering fully human monoclonal antibodies from murine variable regions","volume":"396","author":"Bernett","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies","volume":"10","author":"Teisseyre","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO-25-02587","article-title":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline","volume":"44","author":"Hicks","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zamanillo, I., Medina de Alba, L., Gil, R., de la Puerta, R., Alonso, R., Jimenez-Ubieto, A., Cedena, M.T., Calbacho, M., Ayala, R., and Martinez-Lopez, J. (2023). Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure. Life, 13.","DOI":"10.3390\/life13091841"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Saltarella, I., Desantis, V., Melaccio, A., Solimando, A.G., Lamanuzzi, A., Ria, R., Storlazzi, C.T., Mariggi\u00f2, M.A., Vacca, A., and Frassanito, M.A. (2020). Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9010167"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/bjh.20106","article-title":"Multiple myeloma with 1q gain\/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression","volume":"206","author":"Kuroki","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1182\/blood.2024025899","article-title":"Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy","volume":"144","author":"Chakraborty","year":"2024","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Costa, F., Dalla Palma, B., and Giuliani, N. (2019). CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents. Cells, 8.","DOI":"10.3390\/cells8121632"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70213","DOI":"10.1002\/jev2.70213","article-title":"Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma","volume":"15","author":"Brennan","year":"2026","journal-title":"J. Extracell. Vesicles"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bcpt.14054","article-title":"Mechanisms of resistance to daratumumab in patients with multiple myeloma","volume":"135","author":"Iversen","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2314322","DOI":"10.1080\/15384047.2024.2314322","article-title":"CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells","volume":"25","author":"Wang","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ndt\/gfaf127","article-title":"Urinary rituximab loss and rate of treatment failure in membranous nephropathy","volume":"41","author":"Allinovi","year":"2025","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/jcph.121","article-title":"Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease","volume":"53","author":"Roberts","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Arriv\u00e9, C., Jacquet, M., Gautier-Veyret, E., Jouve, T., Noble, J., Lombardo, D., Rostaing, L., and Stanke-Labesque, F. (2023). Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab-A Preliminary Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12227141"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: Prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41375-021-01501-0","article-title":"Tracking daratumumab clearance using mass spectrometry: Implications on M protein monitoring and reusing daratumumab","volume":"36","author":"Abdallah","year":"2022","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/ijmr.IJMR_312_19","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences","volume":"155","author":"Saffari","year":"2022","journal-title":"Indian J. Med. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Boyer-Suavet, S., Andreani, M., Lateb, M., Savenkoff, B., Brglez, V., Benzaken, S., Bernard, G., Nachman, P.H., Esnault, V., and Seitz-Polski, B. (2020). Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2019.03069"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-024-03297-7","article-title":"Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis","volume":"26","author":"Pollastro","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-022-04418-2","article-title":"Anti-drug antibodies in the current management of cancer","volume":"89","author":"Ramos","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1208\/s12248-024-00954-2","article-title":"Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates","volume":"26","author":"Usdin","year":"2024","journal-title":"AAPS J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19253","DOI":"10.1038\/s41598-021-98700-7","article-title":"Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma","volume":"11","author":"Sasson","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1424674","DOI":"10.1080\/2162402X.2018.1424674","article-title":"Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab","volume":"7","author":"Kverneland","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tourdot, S., Vazquez-Abad, M.D., Cox, D.S., Cai, C.H., Wang, K., Zhang, W., and Lepsy, C. (2025). Antidrug antibodies to adalimumab do not associate with immunologically related adverse events. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1457993"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamadermatol.2013.8347","article-title":"Extent and consequences of antibody formation against adalimumab in patients with psoriasis: One-year follow-up","volume":"150","author":"Menting","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Liu, Y., Cheng, Y., Wu, D., Hu, H., Chen, Y., and Wan, Q. (2026). Anti-Obinutuzumab Antibodies in Primary Membranous Nephropathy. Nephrol. Dial. Transpl., gfag104.","DOI":"10.1093\/ndt\/gfag104"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.15879","article-title":"Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed\/refractory multiple myeloma (GEN503): Final results of an open-label, phase 1\/2 study","volume":"186","author":"Plesner","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): An open-label Phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_54","first-page":"515","article-title":"Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: Final analysis of the phase 3 OCTANS Study","volume":"104","author":"Fu","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S753","DOI":"10.1016\/j.annonc.2025.08.1891","article-title":"Phase I randomized, double-blind, parallel study to compare pharmacokinetics, safety, and immunogenicity of QL2109 with daratumumab and hyaluronidase-fihj in healthy male participants","volume":"36","author":"Hu","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: An open-label, single-arm, multicenter, phase 2 study","volume":"14","author":"Huang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Vultaggio, A., Perlato, M., Nencini, F., Vivarelli, E., Maggi, E., and Matucci, A. (2021). How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.765747"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: Ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","article-title":"Infusion reactions: Diagnosis, assessment, and management","volume":"14","author":"Vogel","year":"2010","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jim.2010.11.011","article-title":"Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development","volume":"365","author":"Mikulskis","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-023-01240-8","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab","volume":"62","author":"Kim","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/jcph.1771","article-title":"Exposure-response and population pharmacokinetic analyses of a novel subcutaneous formulation of daratumumab administered to multiple myeloma patients","volume":"61","author":"Luo","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/bcp.15628","article-title":"Population pharmacokinetics and exposure\u2013response analyses of daratumumab plus pomalidomide\/dexamethasone in relapsed or refractory multiple myeloma","volume":"89","author":"Dosne","year":"2023","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/4\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:59:54Z","timestamp":1783069194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/4\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["antib15040057"],"URL":"https:\/\/doi.org\/10.3390\/antib15040057","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}